EUCTR2009-015834-31-NL进行中（未招募）不适用
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction - PARADIGM-HF
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 7,980
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients must give written informed consent before any assessment is performed.
- •2.Outpatients = 18 years of age, male or female.
- •3.Patients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction:
- •o LVEF = 40% at Visit 1 (any local measurement, made within the past 6 months using echocardiography, MUGA, CT scanning, MRI or ventricular angiography is acceptable, provided no subsequent measurement above 40%)
- •o BNP = 150 pg/ml (NT-proBNP = 600 pg/ml) at Visit 1 OR BNP = 100 pg/mL (NT-proBNP = 400 pg/ml) and a hospitalization for HF within the last 12 months
- •4.Patients must be on an ACEI or an ARB at a stable dose of at least enalapril 10 mg/d or equivalent for at least 4 weeks before Visit 1
- •o For this protocol doses of other ACEIs considered to be equivalent to enalapril 10 mg/d include captopril 100 mg/d, cilazapril 2.5 mg/d, fosinopril 20 mg/d, lisinopril 10 mg/d, moexipril 7.5 mg/d, perindopril 4 mg/d, quinapril 20 mg/d, ramipril 5 mg/d, trandolapril 2 mg/d, and zofenopril 30 mg/d.
- •o For this protocol doses of ARBs considered to be equivalent to enalapril 10 mg/d include candesartan 16 mg/d, eprosartan 400 mg/d, irbesartan 150 mg/d, losartan 50 mg/d, olmesartan 10 mg/d, telmisartan 40 mg/d, and valsartan 160 mg/d.
- •5. Patients must be treated with a ß-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to Visit 1 (reason should be documented for patients not on CHF target doses per local guidelines, or in absence of that medication).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
- •2.History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drugs
- •3.Previous history of intolerance to recommended target doses of ACEIs or ARBs
- •4.Known history of angioedema
- •5.Requirement of treatment with both ACEIs and ARBs
- •6.Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)
- •7.Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 (screening) or < 95 mmHg at Visit 3 or at Visit 5 (randomization)
- •8.Estimated GFR < 30 mL/min/1.73m2 as measured by the simplified MDRD formula at Visit 1 (screening), Visit 3 (end of enalapril run-in), or Visit 5 (end of LCZ696 run-in and randomization) or > 25% decline in eGFR between Visit 1 and Visit 3 or between Visit 1 and Visit 5
- •9.Serum potassium > 5.2 mmol/L at Visit 1 (screening) or > 5.4 mmol/L at Visit 3 or Visit 5 (randomization)
- •10.Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty within the 3 months prior to Visit 1
- •11.Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after Visit 1
- •12.Implantation of a cardiac resynchronization therapy device (CRTD) within 3 months prior Visit 1 or intent to implant a CRTD
- •13.History of heart transplant or on a transplant list or with left ventricular assistance device (LVAD)
- •14.History of severe pulmonary disease
- •15.Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the 12 months prior to Visit 1
- •16.Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months prior to Visit 1
- •17.Symptomatic bradycardia or second or third degree heart block without a pacemaker
- •18.Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation
- •19.Presence of other hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis
- •20.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including but not limited to any of the following:
- •o History of active inflammatory bowel disease during the 12 months before Visit 1.
- •o Current duodenal or gastric ulcers during the 3 months prior to Visit 1
- •o Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x ULN at Visit 1, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt
- •o Active treatment with cholestyramine or colestipol resins
- •21.Presence of any other disease with a life expectancy of < 5 years
- •22.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)
- •23.Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasec
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV) - ATMOSPHEREchronic heart failure (NYHA Class II - IV)MedDRA version: 16.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2008-004104-31-SEovartis Pharma Services AG7,046
进行中（未招募）
不适用
This study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality of patients with chronic heart failure.MedDRA version: 15.1Level: LLTClassification code 10008502Term: CHFSystem Organ Class: 100000004849Chronic Heart FailureEUCTR2009-015834-31-DEovartis Pharma Services AG7,980
进行中（未招募）
1 期
A multicenter, randomized, double-blind, Phase 2 study to assess ATX01 (topical study drug) in comparison to placebo, in cancer adult patients with chemotherapy-induced peripheral neuropathy (CIPN)chemotherapy-induced peripheral neuropathy (CIPN)MedDRA version: 20.1Level: LLTClassification code 10079545Term: Chemotherapy induced peripheral neuropathySystem Organ Class: 100000004852EUCTR2022-000435-23-CZAlgoTherapeutix240
进行中（未招募）
1 期
Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patientscomplement 3 glomerulopathyMedDRA version: 20.0Level: PTClassification code 10077827Term: C3 glomerulopathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-004589-21-SKovartis Pharma AG83
进行中（未招募）
1 期
A clinical trial to evaluate efficacy and safety of aliskiren and aliskiren/enalapril combination compared to enalapril in patients with heart failure.Chronic heart failure (NYHA Class II - IV)MedDRA version: 16.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2008-004104-31-IEovartis Pharma AG7,046